PTC/SB/08s (08-03 )
Approved for use through 97/31/2006. OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unfees it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are regarded to respect to a calciform of information United us a shift Collection of information unless it contains a valid CMS control number

Application Number

Filling Date

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor	Charl	les Mason
Art Unit		
Examiner Name		
Attamen Dealest Numb		AD442.00

				U.	S.PATENTS			Remove	
Examiner Cite Initial* No Patent Number Kind Code			Kind Code <sup>1</sup>	Issue Date  Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear			
	1	6721783	B1	2004-04-13	Biossman G	ary B. et al.			
	2	5699528	A	1997-12-16	Hogan et al.				
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information	please click th	e Add button.		Add	
			U.S.P	ATENT APP	LICATION PU	BLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant R		Relevan	Columns,Lines whe nt Passages or Rel Appear	
	1	dd additional U.S. Pub						Add	
ii you wisi	n to a	od additional U.S. Pub			ATENT DOCU			Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Publication le <sup>4</sup> Date	Name of Patente Applicant of cited Document	e or w	ages,Columns,Line here Relevant assages or Releva igures Appear	76
	1	02/23785	wo	A	2002-03-21	Innovation Venture	,		С
			1				- 1		

	Application Number		
NEODIA TION DIOCI COURT	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Charl		les Mason
( Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	er	AP113-06

	3	1067	472	EP	A	2001-01-10	Swedgiro AB			
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
				NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	Cite No								Тs	
	1 DR. G. JAKEL, 'Re: get EKA', Online! 28 January 2001, robol@1822DIREKT.COM, Internet.									
If you wish to add additional non-patent literature document citation information please click the Add button Add										
	EXAMINER SIGNATURE									
Examiner	Examiner Signature Date Considered									

See Kint Codes of USPTO Patent Documents at Iwan USPTO\_GDV or MPEP 901.04. Enter office that issued the document, by the Nov-letter office (WIPO Standard ST3.) For Explanese patent document, the Indication of the year of the region or preceded the serial number of the Emptor or unpreceded the serial number of patent document. If kind of coursent by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Speciant is to place a check mark here if Emptor Indication is attached.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# Application Number Filing Date Filing Date Filing Date First Number Inventor Charles Mason Art Unit Examiner Name Attorney Docket Number AP113-06

## CERTIFICATION STATEMENT

Diagra can	37 CER	1 97	and 1 98 to	make the	annronniata	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

# ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement.

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David A. Guerra/	Date (YYYY-MM-DD)	2006-09-19
Name/Print	David A. Guerra	Registration Number	46443

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.